FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma
The FDA has cleared elranatamab-bcmm for multiple myeloma under its accelerated approval pathway, according to the agency's own posting.
The U.S. Food and Drug Administration has granted accelerated approval to elranatamab-bcmm for the treatment of multiple myeloma, as stated in the agency's drug approval notice.
FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma1, according to the posted record.
The document provided does not include further details such as the specific indication criteria, dosing regimen, trial data supporting the approval, or the date the approval was issued. Readers seeking those specifics should consult the full FDA announcement and the underlying prescribing information once available.
This outlet will update this report with additional detail, including trial results and labeling information, as more of the FDA's documentation becomes available.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.